Small nonphosphorylated Grb2-SH2 domain antagonists evaluated by surface plasmon resonance technology

Area of Science:

• Biochemistry
• Molecular Biology
• Medicinal Chemistry

Background:

• The Grb2-SH2 domain is integral to the Ras signal transduction pathway, regulating cell proliferation and differentiation.
• Dysregulation of this pathway is implicated in oncogenesis, making the Grb2-SH2 domain a target for antiproliferative drug development.

Purpose of the Study:

• To investigate the inhibitory effects of small, nonphosphorylated peptide analogs on the Grb2-SH2 domain.
• To identify potent peptide inhibitors for potential antiproliferative agents.

Main Methods:

• Synthesis, purification, and characterization of eight related peptide analogs.
• Evaluation of inhibitory effects using surface plasmon resonance (SPR) technology on a BIACORE X instrument.
• Molecular modeling to elucidate the binding interactions of the lead peptide with the Grb2-SH2 domain.

Main Results:

• The lead peptide, Fmoc-Glu-Tyr-Aib-Asn-NH2 (Fmoc-E-Y-Aib-N), demonstrated significant inhibition of Grb2-SH2 domain function with an IC50 of 8.7 microM.
• Molecular modeling revealed key interactions, including a salt bridge between the peptide's glutamate and Arg 67, and inward flipping of Grb2-SH2 residue Glu 89.
• These interactions suggest a mechanism where the peptide mimics or replaces the function of the phosphate group in binding.

Conclusions:

• The developed nonphosphorylated peptide analogs show promise as inhibitors of the Grb2-SH2 domain.
• The lead peptide, Fmoc-E-Y-Aib-N, provides a foundation for designing more potent antiproliferative agents targeting the Ras pathway.
• These findings offer valuable insights for the rational design of novel peptide-based therapeutics for cancer treatment.